Keratoconjunctivitis vernalis

Zusammenfassung

Die vernale Keratokonjunktivitis (VKC) gehört zu den allergischen Erkrankungen. Das Auftreten variiert erheblich in Abhängigkeit von der Klimazone. Kommt die VKC in gemäßigten Klimazonen nur saisonal vor, so finden sich in den Tropen meist ganzjährige und schwere Verläufe. Am häufigsten sind Jungen in der 1. Lebensdekade betroffen. Pathophysiologische Besonderheit ist ein dichtes, gemischtzelliges Infiltrat unter dem z. T. extrem verdickten Epithel. Es zeigen sich ausgeprägte Kapillarproliferationen, Fibrozytenstränge und eine verbreiterte extrazelluläre Matrix. Die Entzündungsreaktionen schließen IgE-und nicht IgE-vermittelte Entzündungsreaktionen ein. Das klinische Bild zeichnet sich durch ausgeprägte subjektive Symptome und die Entstehung von Riesenpapillen der oberen tarsalen Bindehaut aus. Unterschieden werden eine limbale und eine palpebrale Form. Hornhautveränderungen sind die bedrohlichsten Komplikationen mit Entwicklung von Hornhauterosionen und Ulzera. Therapeutisch kommen vorwiegend Präparate zum Einsatz, welche die Freisetzung von entzündlichen Botenstoffen wie das Histamin blockieren. Dies sind meist lokale Antihistaminika, Mastzellstabilisatoren und Dual-Action-Präparate. Topische Steroide oder topische Calcineurininhibitoren sind schweren Verläufen vorbehalten. Gleiches gilt auch für den Einsatz von systemischen Kortikosteroiden oder neuen Biologika, z. B. IgE-Inhibitoren. Eine operative Therapie ist insbesondere bei Hornhautkomplikationen erforderlich. In den Phasen einer akuten Entzündung mit der Gefahr von sehbedrohenden Komplikationen ist eine Therapie immer angezeigt.

Abstract

Vernal keratoconjunctivitis (VKC) belongs to the group of allergic eye diseases. The incidence varies considerably, depending on the climate zone. In temperate climates VKC occurs only seasonally, while in hot climates it is mostly all year-round and rather more severe. Most commonly boys are affected in the first decade of life. Pathophysiological feature is a dense mixed cellular infiltrate with sometimes extremely thickened epithelium. It shows pronounced capillary proliferation, fibrosis and a thickened extracellular matrix. Inflammatory responses can be divided into IgE-mediated and non-IgE mediated inflammation. The clinical picture is characterised by pronounced subjective symptoms and the emergence of giant papillae, mostly on the upper tarsal conjunctiva. Distinction can be made into a limbal form and a palpebral form. Corneal changes are the most threatening complications with development of corneal erosions and shield ulcers. The therapeutic approach uses mainly drugs to block the release of inflammatory mediators such as histamine. These are usually local antihistamines and dual action preparations. Topical steroids or topical calcineurin inhibitors are only used in more severe situations. The same applies for the use of systemic corticosteroids or new biologics e.g., IgE inhibitors. Surgical therapy is predominantly required for the treatment of corneal complications. In general, VKC usually has a self-limiting course. However, during phases of inflammation with the risk of developing vision-threatening complications therapy is always indicated.

Schlüsselwörter

Kornea - Allergie - Immunomodulation - Keratoconjunctivitis vernalis - Konjunktiva

Key words

cornea - allergy - immunomodulation - vernal keratoconjunctivitis - conjunctiva

• Literatur

• 1 Ukponmwan CU. Vernal keratoconjunctivitis in Nigerians: 109 consecutive cases. Trop Doct 2003; 33: 242-245
• 2 McMoli TE, Assonganyi T. Limbal vernal kerato-conjunctivitis in Yaounde, Cameroon. A clinico-immunology study. Rev Int Trach Pathol Ocul Trop Subtrop 1991; 68: 157-170
• 3 OʼShea JG. A survey of vernal keratoconjunctivitis and other eosinophil-mediated external eye diseases amongst Palestinians. Ophthalmic Epidemiol 2000; 7: 149-157
• 4 Leonardi A, Busca F, Motterle L et al. Case series of 406 vernal keratoconjunctivitis patients: a demographic and epidemiological study. Acta Ophthalmol Scand 2006; 84: 406-410
• 5 Khan MD, Kundi N, Saeed N et al. Incidence of keratoconus in spring catarrh. Br J Ophthalmol 1988; 72: 41-43
• 6 Tuft SJ, Dart JK, Kemeny M. Limbal vernal keratoconjunctivitis: clinical characteristics and immunoglobulin E expression compared with palpebral vernal. Eye 1989; 3: 420-427
• 7 Allansmith MR, Baird RS, Greiner JV. Vernal conjunctivitis and contact lens-associated giant papillary conjunctivitis compared and contrasted. Am J Ophthalmol 1979; 87: 544-555
• 8 Kato N, Fukagawa K, Dogru M et al. Mechanisms of giant papillary formation in vernal keratoconjunctivitis. Cornea 2006; 25: 47-52
• 9 Montan PG, Ekström K, Hedlin G et al. Vernal keratoconjunctivitis in a Stockholm ophthalmic centre–epidemiological, functional, and immunologic investigations. Acta Ophthalmol Scand 1999; 77: 559-563
• 10 Bonini S, Lambiase A, Schiavone M et al. Estrogen and progesterone receptors in vernal keratoconjunctivitis. Ophthalmology 1995; 102: 1374-1379
• 11 Motterle L, Diebold Y, Enríquez de Salamanca A et al. Altered expression of neurotransmitter receptors and neuromediators in vernal keratoconjunctivitis. Arch Ophthalmol 2006; 124: 462-468
• 12 Montan PG, Biberfeld PJ, Scheynius A. IgE, IgE receptors, and other immunocytochemical markers in atopic and nonatopic patients with vernal keratoconjunctivitis. Ophthalmology 1995; 102: 725-732
• 13 Ballow M, Mendelson L. Specific immunoglobulin E antibodies in tear secretions of patients with vernal conjunctivitis. J Allergy Clin Immunol 1980; 66: 112-118
• 14 Abu El-Asrar AM, Struyf S, Al-Kharashi SA et al. Chemokines in the limbal form of vernal keratoconjunctivitis. Br J Ophthalmol 2000; 84: 1360-1366
• 15 Abu El-Asrar AM, Struyf S, Al-Kharashi SA et al. The T-lymphocyte chemoattractant Mig is highly expressed in vernal keratoconjunctivitis. Am J Ophthalmol 2003; 136: 853-860
• 16 Leonardi A, Jose PJ, Zhan H et al. Tear and mucus eotaxin-1 and eotaxin-2 in allergic keratoconjunctivitis. Ophthalmology 2003; 110: 487-492
• 17 Leonardi A. Vernal keratoconjunctivitis: pathogenesis and treatment. Prog Retin Eye Res 2002; 21: 319-339
• 18 Abu-El-Asrar AM, Al-Kharashi SA, Al-Mansouri S et al. Langerhansʼ cells in vernal keratoconjunctivitis express the costimulatory molecule B7-2 (CD86), but not B7-1 (CD80). Eye 2001; 15: 648-654
• 19 Asada Y, Ebihara N, Funaki T et al. Vernal keratoconjunctivitis with giant papillae on the inferior tarsal conjunctiva. Cornea 2014; 33: 32-34
• 20 Leonardi A, DeFranchis G, Zancanaro F et al. Identification of local Th2 and Th0 lymphocytes in vernal conjunctivitis by cytokine flow cytometry. Invest Ophthalmol Vis Sci 1999; 40: 3036-3040
• 21 Abu El-Asrar AM, Fatani RA, Missotten L et al. Expression of CD23/CD21 and CD40/CD40 ligand in vernal keratoconjunctivitis. Eye 2001; 15: 217-224
• 22 Leonardi A, Fregona IA, Plebani M et al. Th1- and Th2-type cytokines in chronic ocular allergy. Graefes Arch Clin Exp Ophthalmol 2006; 244: 1240-1245
• 23 Leonardi A, Curnow SJ, Zhan H et al. Multiple cytokines in human tear specimens in seasonal and chronic allergic eye disease and in conjunctival fibroblast cultures. Clin Exp Allergy J Br Soc Allergy Clin Immunol 2006; 36: 777-784
• 24 Leonardi A, de Dominicis C, Motterle L. Immunopathogenesis of ocular allergy: a schematic approach to different clinical entities. Curr Opin Allergy Clin Immunol 2007; 7: 429-435
• 25 Leonardi A, Brun P, Abatangelo G et al. Tear levels and activity of matrix metalloproteinase (MMP)-1 and MMP-9 in vernal keratoconjunctivitis. Invest Ophthalmol Vis Sci 2003; 44: 3052-3058
• 26 Leonardi A, Borghesan F, Faggian D et al. Eosinophil cationic protein in tears of normal subjects and patients affected by vernal keratoconjunctivitis. Allergy 1995; 50: 610-613
• 27 Abu El-Asrar AM, Struyf S, van Damme J et al. Role of chemokines in vernal keratoconjunctivitis. Int Ophthalmol Clin 2003; 43: 33-39
• 28 Calonge M, Enríquez-de-Salamanca A. The role of the conjunctival epithelium in ocular allergy. Curr Opin Allergy Clin Immunol 2005; 5: 441-445
• 29 Kumagai N, Fukuda K, Fujitsu Y et al. Synergistic effect of TNF-alpha and either IL-4 or IL-13 on VCAM-1 expression by cultured human corneal fibroblasts. Cornea 2003; 22: 557-561
• 30 Solomon A, Shmilowich R, Shasha D et al. Conjunctival fibroblasts enhance the survival and functional activity of peripheral blood eosinophils in vitro. Invest Ophthalmol Vis Sci 2000; 41: 1038-1044
• 31 Asano-Kato N, Fukagawa K, Okada N et al. TGF-beta1, IL-1beta, and Th2 cytokines stimulate vascular endothelial growth factor production from conjunctival fibroblasts. Exp Eye Res 2005; 80: 555-560
• 32 Micera A, Bonini S, Lambiase A et al. Conjunctival expression of thymosin-beta4 in vernal keratoconjunctivitis. Mol Vis 2006; 12: 1594-1600
• 33 Bielory L. Allergic and immunologic disorders of the eye. Part II: ocular allergy. J Allergy Clin Immunol 2000; 106: 1019-1032
• 34 Bonini S, Sacchetti M, Mantelli F et al. Clinical grading of vernal keratoconjunctivitis. Curr Opin Allergy Clin Immunol 2007; 7: 436-441
• 35 Leonardi A, Lazzarini D, Motterle L et al. Vernal keratoconjunctivitis-like disease in adults. Am J Ophthalmol 2013; 155: 796-803
• 36 Malhotra C, Jain AK, Thapa B. Limbal pseudoepitheliomatous hyperplasia mimicking ocular surface squamous neoplasia in palpebral vernal keratoconjunctivitis. Case Rep Ophthalmol Med 2013; 2013: 527230
• 37 Reddy JC, Basu S, Saboo US et al. Management, clinical outcomes, and complications of shield ulcers in vernal keratoconjunctivitis. Am J Ophthalmol 2013; 155: 550-559
• 38 Karseras AG, Ruben M. Aetiology of keratoconus. Br J Ophthalmol 1976; 60: 522-525
• 39 Cingu AK, Cinar Y, Turkcu FM et al. Effects of vernal and allergic conjunctivitis on severity of keratoconus. Int J Ophthalmol 2013; 6: 370-374
• 40 Kao WW, Vergnes JP, Ebert J et al. Increased collagenase and gelatinase activities in keratoconus. Biochem Biophys Res Commun 1982; 107: 929-936
• 41 Pucci N, Novembre E, Cianferoni A et al. Efficacy and safety of cyclosporine eyedrops in vernal keratoconjunctivitis. Ann Allergy Asthma Immunol 2002; 89: 298-303
• 42 Oray M, Toker E. Tear cytokine levels in vernal keratoconjunctivitis: the effect of topical 0.05 % cyclosporine a therapy. Cornea 2013; 32: 1149-1154
• 43 Labcharoenwongs P, Jirapongsananuruk O, Visitsunthorn N et al. A double-masked comparison of 0.1 % tacrolimus ointment and 2 % cyclosporine eye drops in the treatment of vernal keratoconjunctivitis in children. Asian Pac J Allergy Immunol Launched Allergy Immunol Soc Thail 2012; 30: 177-184
• 44 Vichyanond P, Kosrirukvongs P. Use of cyclosporine A and tacrolimus in treatment of vernal keratoconjunctivitis. Curr Allergy Asthma Rep 2013; 13: 308-314
• 45 Sánchez J, Cardona R. Omalizumab. An option in vernal keratoconjunctivitis?. Allergol Immunopathol (Madr) 2012; 40: 319-320
• 46 de Klerk TA, Sharma V, Arkwright PD et al. Severe vernal keratoconjunctivitis successfully treated with subcutaneous omalizumab. J AAPOS 2013; 17: 305-306
• 47 Singh S, Pal V, Dhull CS. Supratarsal injection of corticosteroids in the treatment of refractory vernal keratoconjunctivitis. Indian J Ophthalmol 2001; 49: 241-245
• 48 Saini JS, Gupta A, Pandey SK et al. Efficacy of supratarsal dexamethasone versus triamcinolone injection in recalcitrant vernal keratoconjunctivitis. Acta Ophthalmol Scand 1999; 77: 515-518
• 49 Fujishima H, Fukagawa K, Satake Y et al. Combined medical and surgical treatment of severe vernal keratoconjunctivitis. Jpn J Ophthalmol 2000; 44: 511-515
• 50 Tanaka M, Takano Y, Dogru M et al. A comparative evaluation of the efficacy of intraoperative mitomycin C use after the excision of cobblestone-like papillae in severe atopic and vernal keratoconjunctivitis. Cornea 2004; 23: 326-329
• 51 Guo P, Kheirkhah A, Zhou W et al. Surgical resection and amniotic membrane transplantation for treatment of refractory giant papillae in vernal keratoconjunctivitis. Cornea 2013; 32: 816-820